Transcriptomic Analysis of Changes in CT26+ Colon Cancer Tumors under Donkey Oil Ketogenic Diet
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
Screening of the genes related to the donkey oil ketogenic diet (DOKD) that affects the growth of CT26+ colon cancer tumors using transcriptome sequencing technology was investigated in this study. Mining the genes and metabolic pathways that respond to DOKD provides a basis for analyzing the mechanism of DOKD in inhibiting tumor growth. BALB/c model mice with CT26+ colon cancer with high consistency were selected and randomly divided into two groups with three replicates, and they were fed either a DOKD or normal diet (ND). The animals were sacrificed after 10 days of treatment. Subsequently, the tumors were excised, and tumor weights and volumes were recorded for analysis. RNA-Seq technology and bioinformatic analysis were used for transcriptome sequencing and results analysis. No significant difference was found in the body weight between the DOKD and ND groups, and the tumors were significantly smaller in the DOKD than those in the ND group. Compared with the ND group, a total of 18 genes were differentially expressed in the DOKD group, of which 12 differentially expressed genes (DEGs) were upregulated, and 6 DEGs were down regulated. These DEGs were annotated into a total of 170 GO items, including 124 in the biological process category, 44 in the molecular function category, and 2 in the cellular composition category. A total of 18 KEGG pathways were involved, mainly enriched in the interleukin (IL)-17 signaling, chemokine signaling, cytokine receptor interaction signaling, tumor necrosis factor signaling, and other important pathways. In addition, this study further examined the role of the TLR4/NF-κB signaling pathway in tumors using western blotting. In summary, DOKD has a significant inhibitory effect on CT26+ colon cancer tumors, and this effect may be closely related to the IL-17, chemokine, cytokine receptor interaction, and tumor necrosis factor signaling pathways, among others.
